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(57) ABSTRACT 
The present invention provides compounds S3I-201.1066 
(Formula 1) and S3I-201.2096 (Formula 2) as selective Stat3 
binding agents that block Stat3 association with cognate 
receptor pTyr motifs, Stat3 phosphorylation and nuclear 
translocation, Stat3 transcriptional function, and conse-
quently induced Stat3-specific antitumor cell effects in vitro 
and antitumor response in vivo. 
20 Claims, 8 Drawing Sheets 
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1 
COMPOUNDS THAT SUPPRESS CANCER 
CELLS AND EXHIBIT ANTITUMOR 
ACTIVITY 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
2 
tive strategy to interfere with Stat3 activation and functions 
and this approach has been exploited in prior work (15-25). 
Leading agents from those earlier studies have been explored 
for rational design in conjunction with molecular modeling of 
5 the binding to the Stat3 SH2 domain (18,19), per the X-ray 
crystal structure of the Stat3 homodimer (26). One of those 
leads, S3I-201 (18) had previously been shown to exert anti-
tumor effects against human breast cancer xenografts via This application is a continuation of U.S. patent applica-
tion Ser. No.13/263,336, filed Feb. 6, 2012,nowU.S. Pat. No. 
8,586,749, which claims the priority of U.S. provisional 10 
application Ser. No. 61/166,865 filed on 6 Apr. 2009 and U.S. 
provisional patent application Ser. No. 61/246,695 filed on 29 
Sep. 2009, each of which is incorporated herein by reference 
mechanisms that involve the inhibition of aberrant Stat3. 
In the present study, key structural information from the 
computational modeling of S3I-201 bound to the Stat3 SH2 
domain facilitated the design of novel analogs of which S3I-
201.1066 and S3-201.2096 show improved Stat3-inhibitory 
in its entirety. 
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH OR DEVELOPMENT 
This invention was made with govermnent support under 
Grant Nos. ROI CAI06439 and ROI CAl28865 awarded by 
the National Institutes of Health. The govermnent has certain 
rights in the invention. 
15 
activity. Both S3I-210.1066 and S3I-201.2096 inhibit Stat3 
activity with IC50 values of35 and 45 µM, respectively. This 
disclosure presents evidence that S3I-201. I 066 interacts with 
the Stat3 protein and disrupts Stat3 binding to its cognate 
pTyr peptide of receptors. Furthermore, S3I-201.1066 
20 induces antitumor cell effects selectively in malignant cells 
harboring aberrant Stat3 and antitumor response in vivo in 
human breast xenografts. 
The Sequence Listing submitted Mar. 24, 2014 as a text file 
named "26150_0004U4 Revised Sequence_Listing.txt," 
created on Mar. 24, 2014, and having a size of2,616 bytes is 25 
hereby incorporated by reference pursuant to 37 C.F.R. 
SUMMARY OF THE INVENTION 
With the foregoing in mind, the present invention advan-
tageously provides a useful expansion of several prior studies 
that have provided the proof-of-concept for the therapeutic 
effects of Stat3 inhibitors in human tumors. The molecular 
§ 1.52( e )(5). 
FIELD OF THE INVENTION 
The present invention relates to the field of drug develop-
ment and, more particularly, to compounds that inhibit cancer 
cells. 
BACKGROUND OF THE INVENTION 
Signal transduction proteins have increased importance in 
carcinogenesis and tumor formation and represent attractive 
targets for the development of novel anticancer therapeutics. 
The Signal Transducer and Activator of Transcription 
(STAT) family of proteins are cytoplasmic transcription fac-
tors with important roles in mediating responses to cytokines 
and growth factors, including promoting cell growth and dif-
ferentiation, and inflanmiation and immune responses (1,2). 
Normal STATs activation is initiated by the phosphorylation 
of a critical tyrosine residue upon the binding of cytokines or 
growth factors to their cognate receptors. The phosphoryla-
tion is induced by growth factor receptor tyrosine kinases, or 
cytoplasmic tyrosine kinases, including Janus kinases or the 
Src family kinases. While pre-existing dimers have been 
detected (3,4), phosphorylation is observed to induce dimer-
ization between two STAT monomers through a phosphoty-
rosine interaction with the SH2 domain. In the nucleus, active 
STAT dimers bind to specific DNA-response elements in the 
promoters of target genes and regulate gene expression. 
30 modeling of the phosphotyrosine (pTyr)-SH2 domain inter-
action in Stat3:Stat3 dimerization, combined with in silica 
structural analysis of the previously reported Stat3 dimeriza-
tiondisruptor, S3I-201, has furnished a diverse set of analogs. 
35 
Herein we disclose that compounds S3I201.1066 and S3I-
201.2096 selectively inhibit Stat3 DNA-binding activity in 
vitro, with IC50 values of35 and 45 µM, respectively. In vitro 
biochemical and biophysical studies show that S3 I-201.1066 
interacts with Stat3 or the SH2 domain, with an affinity (KD) 
40 of 2.74 µM, and disrupts Stat3 binding to the cognate pTyr-
peptide motif, with an IC50 value of 23 µM. Accordingly, 
S3I-201.1066 blocks Stat3 association with the epidermal 
growth factor (EGF) receptor in EGF-stimulated fibroblasts 
or in cancer cells, consequently inhibiting Stat3 phosphory-
45 lation, nuclear translocation and transcriptional activity, 
without affecting the Er~APK pathway. 
Furthermore, treatment with S3I-201. I 066 selectively sup-
pressed the growth, viability, survival and malignant trans-
formation of human breast (MDA-MB-231) and pancreatic 
50 (Panc-1) cancer lines and v-Src-transformed mouse fibro-
blasts harboring aberrant Stat3, and down-regulated the 
expression ofknown Stat3-regulated genes, including c-Myc, 
Bcl.xL, the matrix metalloproteinase 9, and VEGF. Impor-
tantly, treatment with S3I-201.1066 induced strong tumor 
55 regression in xenografts of the human breast cancer line 
MDA-MB-231. 
It is now well established that aberrant activation of the 
member of the family, Stat3 contributes to malignant trans-
formation and tumorigenesis. Aberrant Stat3-mediated onco-
genesis and tumor formation is due in part to the transcrip-
tional upregulation of critical genes, which in turn lead to 60 
dysregulation of cell growth and survival, and the promotion 
Taken together, the present disclosure identifies com-
pounds S3I-201.1066 (Formula I) and S3I-201.2096 (For-
mula 2) as selective Stat3 binding agents that block Stat3 
association with cognate receptor pTyr motifs, Stat3 phos-
phorylation and nuclear translocation, Stat3 transcriptional 
function, and consequently induced Stat3-specific antitumor 
cell effects in vitro and antitumor response in vivo. 
of angiogenesis (2,5-11) and tumor immune-tolerance (12, 
13 ). Thus, targeting of aberrant Stat3 signaling would provide 
a novel strategy for treating the wide variety of human tumors 
that harbor abnormal Stat3 activity. 
The critical step of dimerization (14) between two mono-
mers within the context of STAT activation presents an attrac-
65 Accordingly, the present disclosure provides a novel com-
pound, analog of S31-201, according to Formula I, as set 
forth below and in FIG. 1, and salts thereof. 





of treatment effective to inhibit a cancer cell by contacting the 
cell with said compound; a method of treatment effective to 
inhibit a human pancreatic cancer cell by contacting the cell 
with said compound; a method of treatment effective to 
inhibit a human breast cancer cell by contacting the cell with 
said compound; a method of treatment effective to inhibit a 
cell characterized by an aberrant level of Stat3 by contacting 
the cell with said compound; to inhibit a cell characterized by 
an aberrant level of Stat3 by contacting the cell with said \N 
(YN~N/S\ 
HO~ 0 I 
10 compound so as to selectively bind Stat3; to down-regulate 
expression ofStat3-regulated genes in a cell by contacting the 
cell with said compound; to selectively inhibit Stat3-DNA 
binding activity in a cell by contacting the cell with said 
compound, to block Stat3 association with epidermal growth 
0 OH 
(Compound S31-201.1066) 
15 factor receptor in EGF-stimulated fibroblasts by contacting 
the fibroblasts with said compound; and to inhibit tumor cells 
dependent on aberrant Stat3-mediated oncogenesis by con-
tacting the tumor cells with said compound so as to interfere 
with Stat3 function. The disclosure also contemplates that the invention 
includes the compound of Formula 1 used in a pharmaceutical 20 
composition acceptable for administration to a patient. 
Those skilled in the art should recognize that the com-
pounds of this invention may be administered to mammals, 
preferably humans, either alone or in combination with phar-
25 
maceutically acceptable carriers, excipients or diluents, in a 
pharmaceutical composition, according to standard pharma-
ceutical practice. The compounds can be administered by any 
route but are preferably administered parenterally, including 
by intravenous, intramuscular, intraperitoneal, subcutaneous, 30 
rectal and also by topical routes of administration. 
The term "composition" is intended to encompass a prod-
uct comprising the disclosed compounds in amounts effective 
for causing the desired effect in the patient, as well as any 
product which results, directly or indirectly, from combina- 35 
ti on of the specific ingredients. However, the skilled should 
understand that when a composition according to this inven-
tion is administered to a human subject, the daily dosage of 
active agents will normally be determined by the prescribing 
physician with the dosage generally varying according to the 40 
age, weight, sex and response of the individual patient, as well 
as the severity of the patient's symptoms. 
The terms pharmaceutical composition, pharmaceutically 
and/or pharmacologically acceptable for administration to a 
patient refer to molecular entities and/or compositions that do 45 
not produce an adverse, allergic and/or other untoward reac-
tion when administered to a subject, be it animal or human, as 
appropriate. 
As known to the skilled, a pharmaceutically acceptable 
composition or carrier includes any and/or all solvents, dis- 50 
persion media, coatings, antibacterial and/or antifungal 
agents, isotonic and/or absorption delaying agents and/or the 
like. The use of such media and/or agents for pharmaceutical 
active substances is well known in the art. Except insofar as 
any conventional media and/or agent is incompatible with the 55 
active ingredient, its use in the therapeutic compositions is 
contemplated. Supplementary active ingredients can also be 
incorporated into the compositions. For administration, 
preparations should meet sterility, pyrogenicity, general 
safety and/or purity standards as required by FDA Office of 60 
Biologics standards. 
The present disclosure also contemplates a second com-
pound, related to the compound of Formula 1 by both being 
analogs of S3I-201. This second compound is shown below 







The compound of Formula 2 has properties that parallel those 
of the compound of Formula 1 and may be employed in a 
likewise manner, as described above. 
As used herein, the terms "treat," "treating" or "method of 
treatment" refer to both therapeutic treatment and prophylac-
tic or preventive measures, wherein the object is to prevent or 
slow down (lessen) an undesired physiological change or 
disorder, such as the development or spread of cancer or other 
proliferation disorder. For purposes of this invention, benefi-
cial or desired clinical results include, but are not limited to, 
alleviation of symptoms, diminishment of extent of disease, 
stabilized (i.e., not worsening) state of disease, delay or slow-
ing of disease progression, amelioration or palliation of the 
disease state, and remission (whether partial or total), 
whether detectable or undetectable. For example, treatment 
with a compound of the invention may include reduction of 
undesirable cell proliferation, and/or induction of apoptosis 
and cytotoxicity. 
"Treatment" can also mean prolonging survival as com-
pared to expected survival if not receiving treatment. Those in 
need of treatment include those already with the condition or 
disorder as well as those prone to have the condition or 
The skilled will find additional guidance in preparation of 
pharmaceutically acceptable compositions by consulting 
United States Pharmacopeia (USP) or other similar treatises 
employed in the pharmaceutical industry. 
The novel compound of Formula 1, given above, may be 
used in various methods of treatment, for example: a method 
65 disorder or those in which the condition or disorder is to be 
prevented or onset delayed. Optionally, the patient may be 
identified (e.g., diagnosed) as one suffering from the disease 
US 8,895,746 B2 
5 
or condition (e.g., proliferation disorder) prior to administra-
tion of the Stat3 inhibitor of the invention. 
The terms "effective to inhibit" or "growth inhibitory 
amount" of the compounds of the invention refer to an amount 
which reduces (i.e., slows to some extent and preferably 5 
stops) proliferation of a target cell, such as a tumor cell, either 
in vitro or in vivo, irrespective of the mechanism by which 
cell growth is inhibited (e.g., by cytostatic properties, cyto-
6 
complexes in gel are shown, control (-) lane or zero (0) 
represent 0.05% DMSO. Data are representative of2-4 inde-
pendent determinations. 
FIG. 4 shows the effect of S3I-201.1066 on the colocaliza-
tion or association of Stat3 with EGF receptor and on Stat3 
nuclear translocation. (A) Immunofluorescence imaging/ 
confocal microscopy of Stat3 colocalization with EGFR and 
Stat3 nuclear localization in EGF-stimulated (1 g/ml; 10 min) 
NIH3T3/hEGFR pre-treated with or without 50 µM toxic properties, etc.). 
BRIEF DESCRIPTION OF THE DRAWINGS 
Some of the features, advantages, and benefits of the 
present invention having been stated, others will become 
apparent as the description proceeds when taken in conjunc-
tion with the accompanying drawings, presented for solely 
for exemplary purposes and not with intent to limit the inven-
tion thereto, and in which: 
10 S3I-201.1066 for 30 min; or (B) Immunoblotting analysis of 
(i) EGFR immunecomplex (upper panel) or whole-cell 
lysates (lower panel) from S3I201.1066-treated Pane-I and 
MDA-MB-231 cells, or (ii) immunecomplexes ofEGFR (up-
per panel) or Stat3 (lower panel) treated with the indicated 
15 concentrations of S3I-201.1066 and probing for EGFR, 
Stat3, She, Grb 2, or Erkl/2MAPK. Data are representative of 
three independent studies; 
FIG. 5 indicates that S3I-201.1066 suppresses viability, 
growth and survival of malignant cells that harbor persis-
FIG. l(A-C), illustrates structures of(A) S3I-201, (B) S3I-
201.1066 and (C) S3I-201.2096; D and E, GOLD docking of 
(D) S3I-201 (green), and (E) S3I-201.1066 (yellow) and S3I-
201.2096 (green) to the SH2 domain ofStat3; arrow denotes 
potential binding sub-pocket; 
20 tently-active Stat3 Human breast (MDA-MB-231) and pan-
creatic (Panc-1) cancer cells, the normal mouse fibroblasts 
(NIH3T3) and their v-Src transformed (NIH3T3/v-Src) or 
v-Ras transformed (NIH3 T3/v-Ras) counterparts, mouse thy-
mic epithelial stromal cells (TE-71 ), Stat3 null mouse embry-
FIG. 2 shows effects ofS3I-201.1066 and S3I-201.2096 on 
the activities of STATs, Src, Jakl, She, and Erks. (A) Nuclear 
extracts of equal total protein containing activated Stat!, 
Stat3, and/or Stat5 were pre-incubated with or without (i), 
(iii) and (iv) S3I-201.1066 or (ii) S3I-201.2096 for 30 min at 
room temperature prior to the incubation with the radiola-
beled hSIE probe that binds Stat! and Stat3 or the MGFe 
probe that binds Stat5 and subjecting to EMSA analysis; (B) 
Nuclear extracts of equal total protein prepared from malig-
nant cells following 24-h treatment with or without S3I-
201.1066 were subjected to in vitro DNA-binding assay using 
the radiolabeled hSIE probe and analyzed by EMSA; (C) 
Cytosolic extracts of equal total protein were prepared from 
36-h S3I-201.1066-treated or untreated NIH3T3/v-Src fibro-
25 onic fibroblasts (Stat3-/-), and the normal human pancreatic 
duct epithelial cells (HPDEC) were treated once or untreated 
with 30-100 M S3I-201.1066 for 24-144 h. Cells were (A) 
assayed for viability using CyQuant cell proliferation kit; 
IC50 values were derived from graphical representation; (B) 
30 harvested at each 24-h period following treatment and viable 
cells counted by trypan blue exclusion with phase-contrast 
microscopy; or (C) allowed to culture until large colonies 
were visible, which were stained with crystal violet and enu-
merated. Values are the mean and S.D. of 3-4 independent 
35 determinations, p values, *-<0.05, and **-<0.01; 
FIG. 6 demonstrates that S3I-201.1066 blocks Stat3-de-
pendent malignant transformation and inhibits the migration 
of malignant cells harboring aberrant Stat3. (A) Viral Src-
transformed mouse fibroblasts (NIH3 T3/v-Src) and counter-
part transformed by v-Ras (NIH3T3/v-Ras) growing in soft-
agar suspension were treated with or without 30-100 µM 
S3I-201.1066 every 2-3 days until large colonies were vis-
ible, which were stained with crystal violet and enumerated; 
(B) Wound healing assay for effect on cell migration in which 
human breast (MDA-MB-231) and pancreatic (Pane-I) can-
cer cells, and the v-Src transformed mouse fibroblasts 
(NIH3T3/v-Src) and counterparts transformed by v-Ras 
(NIH3 T3/v-Ras) were treated with or without 30-80 µM S3I-
201.1066for12-24 hand allowed to migrate into the denuded 
blasts that stably express the Stat3-dependent luciferase 
reporter (pLucTKS3) and analyzed for luciferase activity 40 
using a luminometer, and (D) SDS-PAGE and Western blot-
ting analysis ofwhole-cell lysates of equal total protein pre-
pared from S3I-201.1066-treated oruntreated NIH3T3/v-Src 
and Pane-I cells probing for pY705Stat3, Stat3, pY416Src, 
Src, pJakl, Jakl, pShc, She, pErkl/2 andErkl/2. Positions of 45 
STATs:DNA complexes or proteins in gel are labeled; control 
lanes (0) represent nuclear extracts treated with 0.05% 
DMSO, or nuclear extracts or whole-cell lysates prepared 
from 0.05% DMSO-treated cells. Data are representative of 
3-4 independent determinations. **-<0.01; 
FIG. 3 depicts studies of the interaction of S31-201.1066 
with Stat3 or the Stat3 SH2 domain. (A) EMSA analysis ofin 
vitro binding of Stat3 to the radiolabeled hSIE probe using 
nuclear extracts containing activated Stat3 preincubated with 
0-100 (µM S31-201.1066 in the presence or absence of 55 
increasing concentrations of purified His-tagged Stat3 SH2 
domain; (B) Surface Plasmon Resonance analysis of the 
binding of (i) GYLPQTV-NH2 (SEQ ID N0:7) (unphospho-
rylated, high affinity gp-130 peptide), (ii) Gp YLPQTV-NH2 
(phosphorylated SEQ ID N0:7), or (iii) small-molecule 531- 60 
201.1066 as analyte to the purified His-tagged Stat3 immo-
bilized on HisCap Sensor Chip; and (C) Fluorescence Polar-
ization assay of the binding to the 5carboxyfluorescein 
GpYLPQTV-NH2 (phosphorylated SEQ ID N0:7) probe of 
50 area. Cell migration was visualized at !Ox magnification by 
light microscopy and cells that migrated into the denuded area 
counted and plotted against the concentration of 
S3I-201.1066. Values are themeanand S.D. of3 independent 
(i) increasing concentration of purified His-Stat3 or (ii) a 65 
fixed amount of purified His-Stat3 (150 nM) in the presence 
of increasing concentrations of 531201.1066. Stat3:DNA 
determinations. p values, *-<0.05, and **-<0.01. 
FIG. 7 shows that S3I-201.1066 suppresses c-Myc, Bcl-
xL, MMP-9 and VEGF expression. SDS-PAGE and Western 
blotting analysis of whole-cell lysates prepared from the 
human breast cancer MDA-MB-231 and pancreatic cancer 
Pane-I cells untreated (DMSO, control) or treated with 
80-100 µM S3I-201.1066 for48 hand probingwithanti-Myc, 
Bcl-xL, MMP-9, VEGF or R-actin antibodies. Positions of 
proteins in gel are shown. Data are representative of 3 inde-
pendent determinations; and 
FIG. 8 shows that S3I-M2001 inhibits growth of human 
breast tumor xenografts. Human breast (MDA-MB231) 
tumor-bearing mice were given S3I-201.1066 (3 mg kg-1) or 
vehicle (0.1 % DMSO in PBS) i.v. every 2 or 3 days. Tumor 
US 8,895,746 B2 
7 8 
Cloning and Protein Expression sizes, measured every 2 or 3 days, were converted to tumor 
volumes and plotted against treatment days; Values are the 
mean and S.D. from replicates of 12 tumor-bearing mice in 
each group. *<0.05. 
Coding regions for the murine Stat3 protein and Stat3 SH2 
domain were amplified by PCR and cloned into vectors pET-
44 Ek/LIC (Novagen) and pET SUMO (Invitrogen), respec-
5 tively. 
DETAILED DESCRIPTION OF PREFERRED 
EMBODIMENTS 
The primers used for amplification were: Stat3 Forward: 
GACGACGACAAGATGGCTCAGTGGAACCAGCTGC 
(SEQ ID NO:l); Stat3 Reverse: GAGGAGAAGCCCGGT-
TATCACATGGGGGAGGTAGCACACT (SEQ ID N0:2); The present invention will now be described more fully 
hereinafter with reference to the accompanying drawings, in 
which preferred embodiments of the invention are shown. 
Unless otherwise defined, all technical and scientific terms 
used herein have the same meaning as commonly understood 
10 Stat3-SH2 Forward: ATGGGTTTCATCAGCAAGGA (SEQ 
ID N0:3); Stat3-SH2 Reverse: TCACCTACAGTACTTTC-
CAAATGC (SEQ ID N0:4). 
Clones were sequenced to verify the correct sequences and 
orientation. His-tagged recombinant proteins were expressed 
15 in BL21(DE3) cells, and purified on Ni-ion sepharose col-
by one of ordinary skill in the art to which this invention 
pertains. Although methods and materials similar or equiva-
lent to those described herein can be used in the practice or 
testing of the present invention, suitable methods and mate-
rials are described below. All publications, patent applica-
tions, patents, or other references mentioned or cited herein 20 
are incorporated by reference in their entirety. In case of 
conflict, the present specification, including any definitions, 
will control. In addition, those of skill in the art should rec-
ognize that the materials, methods and examples given are 
illustrative in nature only and not intended to be limiting. 25 
Accordingly, this invention may be embodied in many differ-
ent forms and should not be construed as limited to the illus-
trated embodiments set forth herein. Rather, the illustrated 
embodiments are provided so that this disclosure will be 
thorough and complete, and will fully convey the scope of the 
invention to those skilled in the art. Other features and advan-
tages of the invention will be apparent from the following 
detailed description, and from the claims. 
unm. 
Nuclear Extract Preparation, Gel Shift Assays, and Densito-
metric Analysis 
Nuclear extract preparations and electrophoretic mobility 
shift assay (EMSA) were carried out as previously described 
(28,33). The 32P-labeled oligonucleotide probes used were 
hSIE (high affinity sis-inducible element from the c-fos gene, 
m67 variant, 5'AGCTTCATTTCCCGTAAATCCCTA; SEQ 
ID N0:5) that binds Stat! and Stat3 (34) and MGFe (mam-
mary gland factor element from the bovine ~-casein gene 
promoter, 5'-AGATTTCTAGGAATTCAA; SEQ ID N0:6) 
for Stat! and Stat5 binding (35,36). Except where indicated, 
nuclear extracts were pre-incubated with compound for 30 
min at room temperature prior to incubation with the radio-
The abbreviations used herein are: STAT, signal transducer 
and activator of transcription; PBST, phosphate-buffered 
saline Tween-200; HPDEC, normal human pancreatic duct 
epithelial cell line; Stat3-/-, Stat3 knockout mouse embry-
onic fibroblasts; PBS, phosphate-buffered saline; 
30 labeled probe for 30 min at 30° C. before subjecting to EMSA 
analysis. Bands corresponding to DNA-binding activities 
were scanned and quantified for each concentration of com-
pound using ImageQuant and plotted as percent of control 
(vehicle) against concentration of compound, from which the 
35 IC50 values were derived, as previously reported (37). 
Immunoprecipitation and SDS-PAGE/Western Blotting 
Analysis 
Immunoprecipitation from whole-cell lysates and SDS/ 
PAGE and Western blotting analysis were performed as pre-
EMSA, electrophoretic mobility shift assay; Erk, extracel-
lular signal-regulated kinase; FBS, fetal bovine serum, 
MMP-9, matrix metalloproteinases 9. 
EXPERIMENTAL PROCEDURES 
40 viously described (33,38). Primary antibodies used were anti-
Stat3, pY705Stat3, pY416Src, Src, pErkl/2, Erkl/2, pJakl, 
Jakl, pShc, She, Grb 2, c-Myc, Bcl-xL, MMP-9, and ~-Actin 
(Cell Signaling, Danvers), and VEGF (Santa Cruz Biotech, 
Santa Cruz). 
45 Cell Viability and Proliferation Assay 
Cells and Reagents Cells in culture in 6-well or 96-well plates were treated 
with or without S3I-201.1066 for 24-144 hand subjected to 
CyQuant cell proliferation assay (Invitrogen Corp/Life Tech-
nologies Corp, Carlsbad, Calif.), or harvested, and the viable 
50 cells counted by trypan blue exclusion with phase contrast 
Normal mouse fibroblasts (NIH3T3) and counterparts 
transformed by v-Src (NIH3T3/v-Src), v-Ras (NIH3T3/v-
Ras) or overexpressing the human epidermal growth factor 
(EGF) receptor (NIH3T3/hEGFR), and the human breast 
cancer (MDA-MB-231) and pancreatic cancer (Pane-I) cells 
have all been previously reported (15,27-29). The normal 
human pancreatic duct epithelial cells (HPDEC) was a kind 
gift from Dr. Tsao, (OCI, UHN-PMH, Toronto) (30), Stat3 
knockout mouse embryonic fibroblasts was generously pro- 55 
vided by Dr. Poli (31 ), and the mouse thymic epithelial stro-
mal cells (TE-71) was a generous gift from Dr. Farr (32). The 
Stat3dependent reporter, pLucTKS3 and the v-Src trans-
formedmouse fibroblasts that stably express pLucTKS3 have 
been previously reported (15, 33). Cells were grown in Dul- 60 
becco's modified Eagle's medium (DMEM) containing 10% 
heat-inactivated fetal bovine serum, or in the case ofHPDEC, 
they were grown in Keratinocyte-SFM media supplemented 
with 0.2 ng EGF, 30 µg/ml bovine pituitary extract and con-
taining antimycol. Antibodies against Stat3, pY705Stat3, 65 
Src, pY416Src, Jakl, pJakl, She, pShc, Erkl/2, and pErkl/2 
are from Cell Signaling Technology (Danvers, Mass.). 
microscopy. 
Immunofluorescence Imaging/Confocal Microscopy 
NIH3T3/hEGFR cells were grown in multi-cell plates, 
serum-starved for 8 h and treated with or without 
S3I-201.1066 for 30 min prior to stimulation by rhEGF (1 
g/ml) for 10 min. Cells were fixed with ice-cold methanol for 
15 min, washed 3 times in PBS, permeabilized with 0.2% 
Triton® X-100 for 10 min, and further washed 3-4 times with 
PBS. Specimens were then blocked in 1 % BSA for 30 min 
and incubated with EGFR (Santa Cruz) or Stat3 (Cell Signal-
ing Tech) antibody at 1:50 dilution at 4° C. overnight. Sub-
sequently, cells were rinsed 4-5 times in PBS, incubated with 
Alexafluor 546 rat antibody for EGFR detection and Alexa 
fluor 488 rabbit antibody for Stat3 detection (Invitrogen) for 
1 h at room temperature in the dark. Specimens were then 
washed 5 times with PBS, covered with cover slides with 
VECTASHIELD mounting medium containing DAPI, and 
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examined innnediately under a Leica TCS SP5 confocal 
microscope (Germany) at appropriate wavelengths. Images 
were captured and processed using the Leica TCS SP 5 soft-
ware. 
Soft-Agar Colony Formation Assay 
Colony formation assays were carried out in 6-well dishes, 
as described previously (16,3 7). Briefly, each well contained 
1.5 ml of 1 % agarose in Dulbeco's modified Eagle's medium 
10 
and allowed to grow until large colonies were visible. Colo-
nies were stained with crystal violet for 4 hand counted under 
phase-contrast microscope. 
Wound Healing Assay for Migration 
Wounds were made using pipette tips in monolayer cul-
tures of cells in six-well plates. Cells were treated with or 
without increasing concentrations of S3I-201,1066 and 
allowed to migrate into the denuded area for 12-24 hours. The 
migration of cells was visualized at a 1 Ox magnification using as the bottom layer and 1.5 ml of0.5% agarose in Dulbeco's 
modified Eagle's medium containing 4000 or 6000 NIH3T3/ 
v-Src or NIH3T3/v-Ras fibroblasts, respectively, as the top 
layer. Treatment with S3I201.1066 was initiated 1 day after 
seeding cells by adding 80 µl of medium with or without 
S3I20.1.1066, and repeating every 3 days, until large colonies 
were evident. Colonies were quantified by staining with 20 µl 
of 1 mg/ml crystal violet, incubating at 3 7° C. overnight, and 
counting the next day under phase contrast microscope. 
Fluorescence Polarization Assay 
10 an Axiovert 200 Inverted Fluorescence Microscope (Zeiss, 
Giittingen Germany), with pictures taken using a mounted 
Canon Powershot A640 digital camera (Canon USA, Lake 
Success, N.Y.). Cells that migrated into the denuded area 
were quantified. Mice and in vivo tumor studies-Six-week-
15 old female athymic nude mice were purchased from Harlan 
and maintained in the institutional animal facilities approved 
by the American Association for Accreditation of Laboratory 
Animal Care. Athymic nude mice were injected subcutane-
ously in the left flank area with 5xl06 human breast cancer 
Fluorescence Polarization (FP) Assay was conducted as 
previously reported (23), with some modification using the 
phospho-peptide, 5-carboxyfluorescein-GpYLPQTV-NH2 
(phosphorylated SEQ ID N0:7) (where pY represents phos-
pho-Tyr) as probe and Stat3. The FP assay was used to evalu-
20 MDA-MB-231 cells in 100 µL of PBS. After 5 to 10 days, 
tumors of a diameter of3 mm were established. Animals were 
ate the binding of agents to Stat3 and to determine the ability 25 
to disrupt the Stat3:pTyr peptide interaction. A fixed concen-
tration of the fluorescently-labeled peptide probe (10 nM) 
was incubated with increasing concentration of the Stat3 
protein for 30 min at room temperature in the buffer, 50 mM 
NaCl, lOmMHEPES, 1mMEDTA,0.1%NonidetP-40, and 30 
grouped so that the mean tumor sizes in all groups were nearly 
identical, then given S3I-201.1066 intravenously at 3 mg/kg 
every 2 or every 3 days for 17 days and monitored every 2 or 
3 days, and tumor sizes were measured with calipers. Tumor 
volume was calculated according to the formula V=0.52xa2 x 
b, where a, smallest superficial diameter, b, largest superficial 
diameter. 
Statistical Analysis 
Statistical analysis was performed on mean values using 
Prism GraphPad Software, Inc. (La Jolla, Calif.). The signifi-
cance of differences between groups was determined by the 
paired t-test at p<0.05*, <0.01 **,and <0.001 ***. 
Results 
the fluorescent polarization measurements were determined 
using the POLARstar Omega (BMG LABTECH, Durham, 
N.C.), with the set gain adjustment at 35 mP. The Z' value was 
derived per the equation Z'=l-(3 SDbound+3 SD free)/ 
( mP bouna mP free), where SD is the standard deviation and mP 
is the average of fluorescence polarization. In the bound state, 
35 Computer-Aided Design ofS3I-201 Analogs as Stat3 Inhibi-
10 nM 5-carboxyfluorescein-Gp YLPQTV-NH2 (phosphory-
lated SEQ ID N0:7) was incubated with 150 nM purified 
Stat3 protein, while the free (unbound) state was the same 40 
mixture, but incubated with an additional 10 IJM unlabeled 
Ac-GpYLPQTV-NH2 (phosphorylated SEQ ID N0:7). For 
evaluating agents, Stat3 protein (150 nM) was incubated with 
serial concentrations ofS31-201.1066 at 30° C. for 60 min in 
the indicated assay buffer conditions. Prior to the addition of 45 
the fluorescence probe, the protein:S31-201.1066 mixtures 
were allowed to equilibrate at room temperature for 15 min. 
Probe was added at a final concentration of 10 nM and incu-
bated for 30 min at room temperature following which the FP 
measurements were taken using the POLARstar Omega, with 50 
the set gain adjustment at 35 mP. 
Surface Plasmon Resonance Analysis 
SensiQ and its analysis software Qdat (ICX Technologies, 
Oklahoma City, Okla.) were used to analyze the interaction 
between agents and the Stat3 protein and to determine the 55 
binding affinity. Purified Stat3 was innnobilized on a HisCap 
Sensor Chip by injecting 50 g/ml of Stat3 onto the chip. 
Various concentrations of S3I-201.1066 in running buffer 
(lxPBS, 0.5% DMSO) were passed over the sensor chip to 
produce response signals. The association and dissociation 60 
rate constants were calculated using the Qdat software. The 
ratio of the association and dissociation rate constants was 
determined as the affinity (Kn)· 
Colony Survival Assay 
This was performed as previously reported (39). Briefly, 65 
cells were seeded as single-cell in 6-cm dishes (500 cells per 
well), treated once the next day with S3I-201.1066 for 48 h, 
tors. 
Close structural analysis of the lowest Genetic Optimiza-
tion for Ligand Docking (GOLD) (40) conformation of the 
lead Stat3 inhibitor, S3I-201 (yellow) (IC50=86 µM for inhi-
bition of Stat3:Stat3 (18)) (FIG. lA) bound within the Stat3 
SH2 domain (FIG. lD), per the X-ray crystal structure of 
DNA-bound Stat3~ homodimer (26) showed significant 
complementary interactions between the protein surface and 
the compound and identified key structural requirements for 
tight binding. Docking studies permitted in silica structural 
design of analogs of differing Stat3 SH2 domain-binding 
characteristics in order to derive Stat3 inhibitors of improved 
potency and selectivity. GOLD docking studies showed lim-
ited structural occupation of the Stat3-SH2 domain, identify-
ing a potential means for improving inhibitor potency. The 
SH2 domain is broadly composed of three sub-pockets, only 
two of which are accessed by S3I-201 (FIG. lD). Lead agent, 
S3I-201 (FIG. lA) has a glycolic acid scaffold with its car-
boxylic acid condensed with a hetero-trisubstituted aromatic 
species to furnish the amide bond, and a hydroxyl moiety that 
has been tosylated. The ortho-hydroxybenzoic acid compo-
nent is a known pTyr mimetic, and low energy GOLD dock-
ing studies consistently placed this unit in the pTyr-binding 
site, making hydrogen bonds and electrostatic interactions 
withLys591, Ser611, Ser613 andArg609. Due to the strength 
of such interactions between oppositely charged ions, it is 
likely that a considerable portion of the binding between the 
SH2 domain and S3I-201 arises from the pTyr mimetic. The 
Otosyl group binds in the mostly-hydrophobic pocket that is 
derived from the tetramethylene portion of the side chain of 
Lys592 and the trimethylene portion of the side chain of 
Arg595, along with Ile597 and Ile634. Given the potency of 
US 8,895,746 B2 
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S3I-20I towards Stat3 inhibition, a rational synthetic pro-
gram was undertaken to modify and optimize the core scaf-
fold to furnish more potent analogs. We additionally 
exploited key hydrophobic interactions with Phe7I 6, Ile659, 
Val637 and Trp623 (FIG. lD) ingenerating compounds made 5 
ofN-substituted (paracyclohexyl)benzyl analogs (FIGS. 1B 
andC). 
A paper by Fletcher et al. entitled. Disruption ofTranscrip-
tionally Active Stat3 Dimers with Non-Phosphorylated, Sali-
cylic Acid-Based Small Molecules: Potent in vitro and Tumor 10 
Cell Activities, which reports on the details of the design and 
synthesis of the series ofS3I-201 analogs may be used by the 
skilled for guidance in synthesizing the novel compounds 
disclosed herein (4I). 
Inhibition of Stat3 DNA-Binding Activity. 15 
S3I20I analogs derived per in silica structural optimiza-
tion and molecular modeling of the binding to the Stat3 SH2 
domain were synthesized and evaluated in Stat3 DNA-bind-
ing assay in vitro, as previously done (I 8). Nuclear extracts 
containing activated Stat3 prepared from v-Src transformed 20 
mouse fibroblasts (NIH3T3/v-Src) that harbor aberrant Stat3 
were incubated for 30 min at room temperature with or with-
out increasing concentrations of the analogs, S3I201.I066 
and S3I-201.2096, prior to incubation with the radiolabeled 
hSIE probe that binds to Stat3 and Statl and subjecting to 25 
electrophoretic mobility shift assay (EMSA) analysis (I8). 
Stat3 DNA-binding activity was inhibited in a dose-depen-
dent manner by both S3I-201.1066 and S3I201.2096 (FIG. 
2A(i) and (ii)), with average IC50 values of 35±09 µMand 
45±I2 µM, respectively. These values represent 2-3 fold 30 
improvement over the activity of the lead agent, S3I-20I 
(IC50 of 86 µM) (I8), from which the present compounds 
were derived. For selectivity, nuclear extracts containing acti-
vated Statl, Stat3 and Stat5 prepared from EGF-stimulated 
NIH3T3/hEGFR (mouse fibroblasts over-expressing the 35 
human epidermal growth factor receptor, EGFR) were pre-
incubated at room temperature with or without increasing 
concentrations of S3I-201.I066 for 30 min, prior to incuba-
tion with the radiolabeled oligonucleotide probes and sub-
jecting to EMSA analyses, as previously done (I8). EMSA 40 
results of the binding studies using the hSIE probe shows the 
strongest complex ofStat3:Stat3 with the probe (upper band, 
lanes I and 2), which is significantly disrupted at 50 µM 
S3I-201.1066 and completely disrupted at IOO µM 
S3I-201.1066 (FIG. 2A(iii), upper band, lanes 2 and 3). 45 
EMSA analysis further shows a less intense Statl :Stat3 com-
plex (intermediate band), which is similarly repressed at 50 
µMand completely disrupted at IOO µM S3I-201.1066 (FIG. 
2A(iii), lanes 2 and 3 ). By contrast, we observe no significant 
inhibition of the Statl:Statl complex that is of the lowest 50 
intensity (lower band) at 50 µM S3I-201.1066, a moderate 
inhibition at IOO µM S3I-201.1066, while a complete inhibi-
tion occurred at 200 µM S3I-201.I066 (FIG. 2A(iii), lower 
band). Of importance, at the IOO µM S3I-201.1066 concen-
tration at which only a moderate inhibition of Statl :Statl 55 
complex occurred, the larger Stat3:Stat3 complex is com-
pletely dissociated (FIG. 2A, lane 3). Moreover, EMSA 
analysis showed no effect on Stat5:Stat5 complex with the 
MGFe probe, up to 300 µM S3I-201.1066 (FIG. 2A(iv)). 
Thus. S3I-201.I066 preferentially inhibits DNA-binding 60 
activity of Stat3 over that of Statl and Stat5. 
Inhibition of Intracellular Stat3 Activation. 
12 
(MDA-MB-23 I) and human pancreatic cancer (Pane-I) lines 
that harbor aberrant Stat3 activity. 
Twenty-four hours after treatment, nuclear extracts were 
prepared from cells and subjected to Stat3 DNA-binding 
assay in vitro using the radio labeled hSIE probe and analyzed 
by EMSA. Compared to the control (0.05% DMSO-treated 
cells, lane I), nuclear extracts from S3I-201.I066-treated 
NIH3T3/v-Src, Pane-I and MDA-MB-23I cells showed 
dose-dependent decreases of constitutive Stat3 activation, 
with significant inhibition at 50 µM S3I-201.1066 (FIG. 2B, 
compare lanes 2-5, 8IO, and 13-I5 to their respective controls 
(0)). Luciferase reporter studies were performed to further 
determine the effect of S3I-201. I 066 on Stat3 transcriptional 
activity. 
Results show that treatment with S3 I-20 I . I 066 of the v-Src 
transformed mouse fibroblasts (NIH3T3/v-Src) that stably 
express the Stat3-dependent luciferase reporter (pLucTKS3) 
(33) significantly (p<0.01) repressed the induction of the 
Stat3-dependent reporter (FIG. 2C). SDS-PAGE and Western 
blot analysis further showed that treatment with S3I201. I 066 
for 24 h induced a concentration-dependent reduction of 
pTyr705Stat3 levels in NIH3T3/v-Src (FIG. 2C(i), top panel) 
and Pane-I cells (FIG. 2C(ii), top panel), presumably through 
the blockade of Stat3 binding to pTyr motifs of receptors and 
the prevention of de nova phosphorylation by tyrosine 
kinases. 
By contrast, immunoblotting analysis of whole-cell lysates 
from the two cell line models showed no significant effects of 
S3I-201.10866 on the phosphorylation of Src (pY4I6Src), 
JakI (pJak), She (pShc ), and ErkI/2 (pErkI/2) under the same 
treatment conditions, (FIG. 2C (i) and (ii), panels 2-5 from the 
top), except the disappearance of pJakI level in Pane-I cells 
at IOO µM S3I201.I066. Total Stat3, Src, JakI, She and 
ErkI/2 protein levels remained unchanged. We infer that at 
the concentrations that inhibit Stat3 activity. S3I-201.I066 
has minimal effect on Src, JakI, She and ErkI/2 activation. 
In Vitro Evidence that S3I-201.I066 Interacts with Stat3 (or 
SH2 Domain) and Selectively Disrupts Stat3 Binding to Cog-
nate pTyr Peptide Motif of Receptor. 
Given the computational modeling prediction that S3I-
201.I066 interacts with the Stat3 SH2 domain, we deduce 
that S3I201.I 066 blocks Stat3 DNA-binding activity by bind-
ing to the Stat3 SH2 domain, thereby disrupting Stat3:Stat3 
dimerization. To determine therefore ifthe Stat3 SH2 domain 
could interact with S3I-20I.I066, we tested whether the addi-
tion of the recombinant Stat3 SH2 domain into the DNA-
binding assay mixture could intercept the inhibitory effect of 
the agent on Stat3 activity that is observed in FIG. 2A(i). 
Purified histidine-tagged Stat3 SH2 domain (His-SH2) was 
added at increasing concentrations (I-500 ng) to nuclear 
extracts containing activated Stat3 and the mixed extracts 
were subjected to DNA-binding assay in vitro forthe study of 
the effect ofS3I-201.I066, as was done in FIG. 2A(i). EMSA 
analysis shows a strong inhibition by S3I-201.I066 ofStat3 
DNA-binding activity, as shown in FIG. 2A(i), when no His-
SH2 domain was added to the nuclear extracts (FIG. 3A, lanes 
2, 7, and 9 compared to lane I). By contrast, the observed 
S3I-201.0I66-mediated inhibition of Stat3 DNA-binding 
activity was progressively eliminated by the presence of an 
increasing concentration of purified His-SH2 domain (Stat3 
SH2), leading to the full recovery of Stat3 activity when 
recombinant SH2 domain protein was present at I25-500 ng 
(FIG. 3A, lanes 3-6, 8 and IO). Stat3 is constitutively activated in a variety of malignant 
cells, including human breast and pancreatic cancer cells (9, 
IO, 20). Given the effect against Stat3 DNA-binding activity 
in vitro, we evaluated S3I-201.I066 in v-Src transformed 
mouse fibroblasts (NIH3T3/v-Src), human breast cancer 
The preceding studies suggest that S3 I-201. I 066 interacts 
65 with the Stat3 SH2 domain. However, the studies do not 
demonstrate a direct binding to the Stat3 SH2 domain. To 
provide definitive evidence of direct binding to Stat3, bio-
US 8,895,746 B2 
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physical studies were performed. His-tagged Stat3 protein 
(or SH2 domain; 50 ng) was immobilized ona Ni-NTA sensor 
chip surface for Surface Plasmon Resonance analysis of the 
binding of 531201.1066 as the analyte. Association and dis-
sociation measurements were taken and the binding affinity 5 
ofS31-201.1066 for Stat3 was determined using Qdat soft-
ware. Results showed a gradual increase and decrease with 
time in the signals (response unit (RU)) for the association 
and dissociation, respectively, of the agent upon its addition 
to the immobilized His-Stat3 (FIG. 3B(iii)), indicative of the 10 
binding of S31-201.1066 to and dissociation from the Stat3 
protein. The curves depicted interactions between Stat3 and 
S31-201.1066, with a binding affinity, K
0 
of2.74 nM/provid-
ing the first definitive evidence of direct Stat3 binding for 
S31-201 or its derivatives. The interactions also showed a 15 
dependency on the concentration of the S3 l-201.I 066 (FIG. 
3B(iii)). This SPR analysis of the conformational changes in 
His-Stat3 was validated by using the high affinity Stat3-bind-
ing phosphoTyr (pY) peptide, GpYLPQTV-NH2 (phospho-
rylated SEQ ID N0:7) derived from the interleukin-6 recep- 20 
tor (IL-6R) subunit, gp-130 (22,23) (with a K
0 
of 24 nM) 
(FIG. 3B(ii)), and its non-phosphorylated counterpart, 
GYLPQTV-NH2 (SEQ ID N0:7), which showed little evi-
dence of significant binding to Stat3 (FIG. 3B(i)). Interest-
ingly, the dissociation curve for S3 l-201.I 066 showed a large 25 
residual binding to Stat3 between 500-1000 s (FIG. 3B(iii), 
14 
ization signal for the interaction between the fluorescently-
labeled phosphopeptide and Stat3 (FIG. 3C(ii)). The 
inhibitory constant (IC50 value) was derived to be 20± 7 .3 µM, 
which is within the range for the IC50 value (35±9 µM) deter-
mined for the inhibition ofStat3 DNA-binding activity (FIG. 
2A(i)). These findings together indicate that S31-201.1066 
binds to Stat3 or its SH2 domain and disrupts the interaction 
of Stat3 with its pTyr peptide, thereby blocking Stat3 DNA-
binding activity. 
To further verify that S3I-201.1066 disrupts the binding of 
Stat3 to receptors, mouse fibroblasts over-expressing the 
EGF receptor (NIH3 T3/hEGFR) were treated with or without 
the compound prior to stimulation with EGF for I 0 min. Cells 
were then subjected to immunostaining for EGFR (red) and 
Stat3 (green) and analyzed by confocal microscopy for EGF-
induced colocalization of Stat3 and EGFR and for Stat3 
nuclear translocation, as previously performed (17). In the 
resting NIH3T3/hEGFR fibroblasts, EGFR (red) is widely 
localized at the plasma membrane, while Stat3 (green) is 
localized at both the plasma membrane and in the cytoplasm, 
with a minimal co localization with EGFR at the plasma mem-
brane and no visible presence in the nucleus (stained blue for 
DAPI) (FIG. 4A upper panel). Stimulation by EGF of cells 
untreated with S3I-201.1066 induced a strong nuclear pres-
ence of Stat3 (cyan for merged Stat3 (green) and DAPI 
(blue)), as well as co localizations ofEGFR and Stat3 (yellow 
for merged EGFR (red) and Stat3 (green)) at the plasma 
membrane, cytoplasm, and peri-nuclear space (FIG. 4A, bot-
tom left). This EGF-stimulated colocalization between 
EGFR and Stat3 and the Stat3 nuclear localization were both 
strongly blocked when cells were pre-treated with 
S3I-201.1066 before stimulating with EGF (FIG. 4A, bottom 
right compared to non-treated, bottom left), indicating that 
the compound disrupts Stat3 binding to EGFR. We infer that 
I 0-50 µM, 500-1000 s ), compared to the rapid association 
and dissociation of the high affinity peptide to and from Stat3 
with no residual binding of the phosphopeptide (FIG. 3B(ii)). 
The implication of this finding is presently unknown, but may 30 
suggest a slower "off' rate for the dissociation of 
S31-201.1066 from Stat3. Differences in the chemical com-
positions and physicochemical properties would account for 
these different behaviors of interactions with the Stat3 pro-
tein. 35 by blocking Stat3 binding to EGFR, S3I-201.1066 attenuates 
Stat3 phosphorylation/activation and thereby prevents Stat3 
nucleartranslocation. To investigate furtherthe Stat3 interac-
tion with the EGFR receptor and the effect ofS3I-201.1066, 
coimmunoprecipitation with immunoblotting studies were 
The studies so far demonstrate that S3 I 20 I . I 066 interacts 
with Stat3 or the Stat3 SH2 domain (data not shown). The 
interaction with the Stat3 SH2 domain could block the bind-
ing ofStat3 to its cognate pTyrpeptide motifs of receptors. To 
verify that the agent disrupts pTyr-Stat3 SH2 domain inter-
actions, hence Stat3:Stat3 dimerization, we set up a fluores-
cence polarization (FP) study based on the binding of Stat3 to 
the high affinity 5 peptide, GpYLPQTV-NH2 (phosphory-
lated SEQ ID N0:7) (22,23). It has previously been reported 
that Stat3 binds to GpYLPQTV-NH2 (phosphorylated SEQ 
ID N0:7) with a higher affinity than to the Stat3-derived pTyr 
peptide, PpYLKTK (SEQ ID N0:8). This high affinity pep-
tide disrupted Stat3 DNA-binding activity in vitro with an 
IC50 value of0.15 µM (22). The FP assay utilizing the 5car-
boxyfluorescein-Gp YLPQTV-NH2 (phosphorylated SEQ ID 
N0:7) as a probe showed a saturation curve in the fluores-
cence polarization signal (mP) with increasing concentration 
(in µM) of purified His-Stat3 for a robust Z' value of 0.84 
(FIG. 3C(i)), which closely matches the previously reported 
value of0.87 (23). 
Test of the non-phosphorylated, non-labeled GYLPQTV-
NH2 (SEQ ID N0:7) in the FP assay showed no evidence of 
effect on the fluorescent polarization signal (data not shown), 
while as expected, the phosphorylated, unlabeled counter-
part, GpYLPQTV-NH2 (phosphorylated SEQ ID N0:7) 
induced a complete inhibition with an IC50 value of0.3 µM 
(data not shown), consistent with the previously reported 
value of0.25±0.03 µM (23). The FP assay was used to further 
test the computational modeling prediction of the ability of 
S31-201.1066 to disrupt Stat3 interaction with its cognate 
pTyr peptide. Results show that S31-201.1066, in a concen-
tration-dependent marmer, abrogated the fluorescent polar-
40 performed in which EGFR immunecomplex was immuno-
precipitated from whole-cell lysates prepared from treated 
and untreated cancer cells and blotted for Stat3, and for She 
and Grb 2 as negative control. Results showed that EGFR 
immunecomplex precipitated from untreated Panel and 
45 MDA-MB-231 cells contained Stat3, She and Grb 2 (FIG. 
4B(i), lanes I and3, i.p. EGFR, blot Stat3. She, andGrb 2). By 
contrast, treatment of both cell lines with S3I-201.1066 sig-
nificantly diminished the level of Stat3 that associated with 
EGFR in the immunecomplex of equal total protein without 
50 affecting the She or Grb 2 levels that are associated with 
EGFR in the complex. See FIG. 4B(i), lanes 2 and 4, i.p. 
EGFR, blot Stat3, She and Grb 2. Western blotting ofwhole-
cell lysates of equal total protein shows the levels of activated 
and total Erkl/2 are unaffected by the treatment of cells with 
55 S3I-201.1066 (FIG. 4B(i), input, blot pErk and Erk) and the 
Stat3 protein levels remain the same (FIG. 4B(i), input, blot 
Stat3). 
In other studies, EGFR and Stat3 immunecomplexes were 
independently precipitated from whole-cell lysates of 
60 untreated Pane- I cells and complexes of equal total protein 
were directly treated with 0-100 M S3I-201.1066 for 3 hand 
then subjected to Western blotting analysis. Compared to 
untreated samples (FIG. 4B(ii), lane I), results show that the 
direct treatment with S3I-201.1066 of the EGFR immu-
65 necomplex dramatically diminished the level ofStat3 present 
in the complex (FIG. 4B(ii), i.p. EGFR, blot Stat3, lanes 2-4), 
with no visible changes in the levels of She or Grb 2 present 
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in the complex (FIG. 4B(ii), i.p., EGFR, blot She or Grb 2). 
The EGFR levels in the immunecomplexes remained 
unchanged (FIG. 4B(ii), upper band). Similarly, the Stat3 
immunecomplex that is directly treated with S3I-201.1066 
and blotted for EGFR showed strongly reduced EGFR levels, 5 
compared to the untreated Stat3 immunecomplex of equal 
total protein (FIG. 4B(ii), i.p. Stat3, blot EGFR, compare lane 
sion of NIH3T3/v-Src, MDA-MB-231 and Pane-I cells 
treated with S3I-201.1066 was significantly inhibited (FIG. 
6A(ii)-(iv)). By comparison, at concentrations that inhibit 
Stat3, 531-201.1066 showed minimal effect on the soft-agar 
growth ofv-Ras transformed mouse fibroblasts (NIH3T3/v-
Ras) (FIG. 6A(i)). These findings indicate that S3I-201.1066 
selectively suppresses viability, growth, and survival of 
malignant cells harboring aberrant Stat3, and blocks Stat3-
mediated malignant transformation. Thus, these studies dem-
I to lanes 2-4). The Stat3 levels in the immunecomplexes 
remained unchanged(FIG. 4B(ii), i.p. Stat3, blot Stat3).Alto-
gether, these findings strongly indicate that S3I-201.1066 10 
disrupts the binding of Stat3 to cognate receptor motifs, 
thereby blocking Stat3 phosphorylation and nuclear translo-
cation. 
onstrate that Stat3 is important not only for tumor growth, but 
also tumor progression ( 43,44). 
To further investigate the biological effects of 
S3I-201.1066 and to assess the ability to block Stat3-depen-
dent tumor progression processes, a wound healing study was 
performed, as described in "Materials and Methods" section S3I-201.1066 Blocks Growth, Viability, Malignant Transfor-
mation, and the Migration of Cells Harboring Constitutively-
Active Stat3. 
Aberrant Stat3 promotes malignant cell proliferation, sur-
vival and malignant transformation (10, 20, 42). Given that 
S3I201. I 066 disrupts Stat3 activation, we asked the question 
whether this agent is able to selectively decrease the viability 
and growth of malignant cells that harbor aberrant Stat3 activ-
ity. The human breast (MDA-MB-231) and pancreatic cancer 
(Pane-I) lines and the v-Src-transformed mouse fibroblasts 
(NIH3T3/v-Src) that harbor constitutively-active Stat3, as 
well as cells that do not harbor aberrant Stat3 (normal mouse 
fibroblasts (NIH3T3), v-Ras-transformed counterpart fibro-
blasts (NIH3T3v-Ras), Stat3 knockout mouse embryonic 
fibroblasts (MEFs) (Stat3-/-) (31 ), normal human pancreatic 
duct epithelial cells (HPDEC) (30), and mouse thymic epi-
thelial stromal cells (TE-71) cells (3 2)) in culture were treated 
with or without an increasing concentration of S3I-201. I 066 
for up to 6 days and analyzed for viable cell numbers by 
CyQuant cell proliferation/viability kit (FIG. SA) and by 
trypan blue exclusion with phase-contrast microscopy (FIG. 
SB), as described in the "Materials and Methods". 
Compared to the control (DMSO-treated) cells, the mouse 
fibroblasts transformed by v-Src (NIH3T3/v-Src), and the 
MDA-MB-231 and Pane-I cells showed significantly 
reduced viable cell numbers (FIG. SA) and were growth 
inhibited (FIG. SB(ii)-(iv)) following treatment with increas-
ing concentrations ofS3I-201. I 066 for 24-144 h. By contrast, 
the viability (FIG. SA) and growth (FIG. SB(i) and (v)) of 
NIH3T3, Stat3-null MEFs (Stat3-/-), normal human pancre-
atic duct epithelial cells (HPDEC), and the mouse thymus 
epithelial stromal cells (TE71) that do harbor aberrant Stat3 
activity were not significantly altered by up to 200 µM 
S3I201.1066 treatment (FIGS. SA and B, and data not 
shown), with derived IC60 values that are >200 µMm com-
pared to 35, 48, and 37 µM for NIH3T3/v-Src, Pane-I, and 
MDA-MB-231, respectively (FIG. SA, lower panel). These 
findings suggest that S3I-201.1066 exerts preferential bio-
logical effects against malignant cells that harbor constitu-
tively-active Stat3, and at concentrations that inhibit Stat3 
activity, the agent does not affect other cells. 
15 for monitoring the migration of malignant cells and the effect 
of treatment with S3I-201.1066. Significantly reduced num-
bers of MDA-MB-231, Pane-I and NIH3T3/v-Src cells 
migrating into the denuded area were observed following 
12-24 h treatment with S3I-201.1066 (FIG. 6B and data not 
20 shown), with strongly reduced numbers occurring at 50 or 
I 00 µM S3I201.I 066 treatment, and statistically lower num-
bers at 30 M S3I-201.1066 (FIG. 6B). By contrast, the migra-
tion ofNIH3T3/v-Ras fibroblasts was minimally affected by 
the same treatment conditions (FIG. 6B). In the 12-24 h 
25 treatment duration, there was no evidence of apoptosis of the 
treated cells (data not shown). These findings demonstrate 
that S3I-201.1066 selectively suppresses the migration of 
malignant cells that harbor aberrant Stat3. 
S3I-201.1066 Represses the Expression of c-Myc, Bcl-xL, 
30 
VEGF, and MMP-9. 
Known Stat3 downstream target genes are key in the dys-
regulated biological processes promoted by aberrant Stat3 (9, 
20, 42). We sought to validate the inhibitory effect of S3I-
201.I 066 on aberrant Stat3 signaling and to define the under-
lying molecular mechanisms for the antitumor cell effects of 
35 the agent by investigating changes in the induction of known 
Stat3-regulated genes. In the human breast carcinoma, MDA-
MB-231 and pancreatic cancer, Pane-I cell lines that harbor 
constitutively-active Stat3, immunoblotting analysis of 
whole-cell lysates shows the constitutive induction of known 
40 Stat3-regulated genes, including c-Myc, Bcl-xL, VEGF, and 
MMP-9 proteins, which were significantly suppressed in 
response to 48 h-treatment with S3I-201.1066 (FIG. 7 and 
data not shown). These data indicate that S3I-201.1066 suf-
ficiently represses the constitutive induction of Stat3-regu-
45 lated genes, thereby thwarting the effect of aberrant Stat3 in 
terms of eliminating the dysregulation of growth and survival 
that supports the malignant phenotype. The ability of S3I-
201.I 066 to block Stat3 transcriptional activity is also sup-
ported by the data in FIG. 2C. 
50 S3I-201.1066 Inhibits Growth of Human Breast Tumor 
Xenografts. 
We extended these studies to examine the effect of S3I- 55 
Given Stat3 's importance in tumor growth and tumor pro-
gression, we evaluated S3I-201.1066 in xenograft models of 
the human breast cancer (MDA-MB-231) cells that harbor 
aberrant Stat3. Compared to control (vehicle-treated), tumor-
bearing mice, treated (i.v. injection) with S3I-201.1066 at 3 
mg/kg every 2 or 3 days for I 7 days had greatly reduced tumor 
sizes (FIG. 8). Animals remained viable at this dose and 
showed no obvious sign of toxicity. These findings together 
201.1066 in colony survival assay performed as previously 
reported (39). Cultured single-cells were untreated or treated 
once with S3I-201.1066 and allowed to grow until large colo-
nies were visible, which were stained and enumerated. 
60 demonstrate that S3I-201. I 066 induces antitumor cell effects Results showed a dose-dependent suppression of the num-
ber of colonies for the v-Src transformed mouse fibroblasts 
(NIH3T3/v-Src), the human pancreatic cancer, Pane-I and 
the human breast cancer, MDA-MB-231 cells (FIG. SC(ii)-
(iv)). By contrast, minimal effect was observed on the colony 
numbers for mouse fibroblasts transformed by v-Ras 65 
(NIH3T3/v-Ras) that do not harbor constitutively-active 
Stat3 (FIG. SC(i)). Furthermore, growth in soft-agar suspen-
and tumor regression by targeting the Stat3 SH2 domain and 
thereby inhibiting Stat3-mediated tumor processes. 
DISCUSSION 
Computational modeling of the interactions of the Stat3 
SH2 domain with the previously reported Stat3 inhibitor lead, 
US 8,895,746 B2 
17 18 
S3I-201 (18) derived key structural information for optimi- the ability of Stat3 (via SH2 domain) to bind to cognate pTyr 
zation and a rational synthetic program that furnished excit- motifs on receptors and thereby block de nova phosphoryla-
ing new analogs. The compounds disclosed herein. ti on by tyrosine kinases, as well as disrupt pre-existing Stat3: 
S3I-201.1066 (Formula 1) and S3I-201.2096 (Formula 2) Stat3 dimers, particularly in malignant cells that harbor aber-
show improved Stat3-inhibitory potency and selectivity in 5 rant Stat3. Indeed, our study shows a strong association of 
vitro, with intracellular Stat3-inhibitory activity that is Stat3 with EGFR in ligand-stimulated mouse fibroblasts or in 
enhanced 2-3-fold. Analog S3I-201.1066 exhibited an cancer cells, and a strong presence in the nucleus of stimu-
improved target selectivity and showed a minimum inhibitory lated cells. Both the Stat3 :EGFR association and the Stat3 
effect on the phosphorylation ofSrc, Jakl' Erkl/2MAPK and nuclear presence are blocked by S31201.1066, indicating that 
She proteins at concentrations (30-50 µM) that inhibit intra- 10 by disrupting Stat3 binding to receptors, S31-201.1066 pre-
cellular Stat3 activation, despite there being SH2 domains 
vents Stat3 phosphorylation, activation, and nuclear translo-
involved in the mechanisms leading to the activation of these 
cation, thereby attenuating Stat3 function. other proteins. Per molecular modeling, the improved activity 
Substantive evidence demonstrates that aberrant Stat3 could in part be due to the enhanced interactions with the 
Stat3 protein, possibly by the (para cyclohexyl)benzyl moiety 15 activity promotes cancer cell growth and survival (15, 16, 29, 
that extends from the scaffold amide nitrogen and makes 46,47),andinducestumorangiogenesis(48,49)andmetasta-
important contacts with the hydrophobic residues Trp623, sis ( 43,49). Accordingly, inhibitors of Stat3 activation and 
Ile659, Val637 and Phe716 within the unexplored pocket. signaling have been shown to induce antitumor cell effects 
The native Stat3 peptide inhibitor, PpYLKTK (SEQ ID consistent with the abrogation of Stat3 function (15-19, 37, 
N0:8) (where pY represents pTyr) and its peptidomimetic 20 50-52). 
analogs (15,16) and several other Stat3 SH2 domain-binding The present disclosure parallels these published reports in 
and dimerization disrupting peptides and their derivatives showing that S3I-201.1066 induces growth inhibition and 
have been reported (21,22,25). Previous studies have utilized loss of viability and survival of the human pancreatic cancer 
the fluorescence polarization analysis to characterize the Pane-I and breast cancer MDA-MB-231 cells, and of the 
binding of the native, high affinity phosphopeptide, 25 v-Src transformed mouse fibroblasts (NIH3T3/v-Src), which 
GpYLPQTV-NH2 (phosphorylated SEQ ID N0:7) (as Scar- are restricted to malignant cells that harbor aberrant Stat3, 
boxyfluorescein-Gp YLPQ TV-NH2 (phosphorylated SEQ while the effects on normal human pancreatic duct epithelial 
ID N0:7)) to the Stat3 protein (22,23 ). Using this assay cells, normal mouse fibroblasts, mouse thymic epithelial stro-
platform and surface plasmon resonance analysis, we provide ma! cells, the viral Ras-transformed mouse fibroblasts that do 
definitive evidence for the physical interaction of 30 not harbor aberrant Stat3, and the Stat3 knockout mouse 
S31-201.1066 with Stat3 or its SH2 domain, with an affinity embryonic fibroblasts (Stat3-/-) (31) are minimal. 
(KD) of2.3 µM. Moreover, S3I-201.1066-induced antitumor cell effects 
The analysis of the interaction reveals a slower kinetics of occurred at significantly lower concentrations, 30-50 µM, 
the association and dissociation, which contrasts the more than the 100 µM activity previously reported for the lead 
rapid binding and dissociation of the native, high affinity 35 agent (18). Mechanistic insight into the is biological effects of 
peptide, Gp YLPQTV-NH2 (phosphorylated SEQ ID N0:7) S3I-201.1066 as a Stat3 inhibitor is provided by the evidence 
to and from Stat3, with a corresponding affinity (KD) of 24 of a suppression of the constitutive expression of known 
nM. The implication of these differences in the binding kinet- Stat3-regulated genes, including c-Myc, Bcl-xL, VEGF and 
ics in relation to the modulation of Stat3 function is presently MMP-9, and the disruption of the Stat3 binding to receptor, 
unclear. 40 which control cell growth and apoptosis, promote tumor 
The second supporting evidence for the interaction of angiogenesis, or modulate invasion (19, 43, 46, 49, 53, 54). 
S31201.1066 with Stat3 comes by way of the disruption by The exclusion ofStat3 from the nucleus further contributes to 
S31-201.1066 of the Stat3 binding to the pTyr peptide in a the inhibition of Stat3 transcriptional function. We further 
fluorescent polarization assay based on the high affinity pep- note the significant antitumor effect of S3I-201.1066 in 
tide, 5carboxyfluorescein-GpYLPQTV-NH2 (phosphory- 45 human breast tumor xenografts. Altogether the present dis-
lated SEQ ID N0:7) probe and Stat3, with a derived IC50 of closure provides evidence for the binding ofS3I-201.1066 to 
45 µM. Stat3, disruption of Stat3:pTyr interactions and hence Stat3: 
By comparison, the unlabeled, native phosphopeptide dis- Stat3 dimerization, and the disruption of the Stat3 binding to 
rupts this interaction between the probe and Stat3, with an receptor, phosphorylation and nuclear translocation. 
IC50 value of 0.3 µM, which is in line with similar reported 50 Accordingly, in the drawings and specification there have 
studies of the high affinity peptide (22,23) that derived an been disclosed typical preferred embodiments of the inven-
affinity of 0.15±0.01 µM (23) and an IC50 value of tionandalthoughspecifictermsmayhavebeenemployed, the 
0.290±0.063 µM (21 ). The higher affinity of the native pep- terms are used in a descriptive sense only and not for purposes 
tide for the protein should be expected, given the more favor- of limitation. The invention has been described in consider-
able physicochemical properties that will facilitate a stronger 55 able detail with specific reference to these illustrated embodi-
binding to the Stat3 protein. ments. It will be apparent, however, that various modifica-
Overall, our study provides support for the binding of tions and changes can be made within the spirit and scope of 
S31-201.1066 to Stat3, and for its ability to disrupt the inter- the invention as described in the foregoing specification and 
action between Stat3 and its cognate pTyr peptide, an event as defined in the appended claims. 
that is indicative of Stat3: Stat3 dimerization. Although other 60 
Stat3 dimerization disruptors have been previously identified 
through molecular modeling (19,45), the present study is the 
first to provide biophysical evidence for a direct interaction of 
a small-molecule, dimerization disruptor with the Stat3 pro-
tein. Given the disruption of the Stat3 binding to the cognate 65 
peptide, GpYLPQTV-NH2 (phosphorylated SEQ ID N0:7), 
we infer that inside cells, S31-201.1066 may interfere with 
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SEQUENCE LISTING 
<160> NUMBER OF SEQ ID NOS, 8 
<210> SEQ ID NO 1 
<211> LENGTH, 34 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic construct; Murine, PCR amplification 
primer, Stat3 Protein Forward 
<400> SEQUENCE, 1 
gacgacgaca agatggctca gtggaaccag ctgc 
<210> SEQ ID NO 2 
<211> LENGTH, 40 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
34 
<223> OTHER INFORMATION, synthetic construct; Murine, PCR amplification 
primer, Stat3 Protein Reverse 
<400> SEQUENCE, 2 
gaggagaagc ccggttatca catgggggag gtagcacact 
<210> SEQ ID NO 3 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic construct; Murine, PCR Primer for 
Stat3-SH2 domain, Forward 
<400> SEQUENCE, 3 
atgggtttca tcagcaagga 
<210> SEQ ID NO 4 
<211> LENGTH, 24 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic construct; Murine, PCR Primer for 
Stat3-SH2 domain, Reverse 
<400> SEQUENCE, 4 
tcacctacag tactttccaa atgc 
<210> SEQ ID NO 5 
<211> LENGTH, 24 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic construct; high affinity sis-
inducible element from c-fos gene 
<400> SEQUENCE, 5 
agcttcattt cccgtaaatc ccta 
<210> SEQ ID NO 6 
<211> LENGTH, 18 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: synthetic construct; Bovine beta-casein gene 









<210> SEQ ID NO 7 
<211> LENGTH, 7 
<212> TYPE, PRT 
23 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
US 8,895,746 B2 
-continued 
<223> OTHER INFORMATION, synthetic construct; gpl30 peptide 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (2) .. (2) 
<223> OTHER INFORMATION, Y at position 2 can be phosphorylated 
<400> SEQUENCE, 7 
Gly Tyr Leu Pro Gln Thr Val 
1 5 
<210> SEQ ID NO 8 
<211> LENGTH, 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic construct; Stat3 derived pTyr peptide 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (2) .. (2) 
<223> OTHER INFORMATION, Y at position 2 is phosphorylated 
<400> SEQUENCE, 8 




That which is claimed is: 
1. A method effective to inhibit a cancer cell, comprising 
the step of contacting the cell with a compound and salts 
thereof according to Formula 1 or Formula 2: 
2. The method of claim 1, wherein the compound and salts 






HO~ 0 I o~~· °'" 
(YNTIN/s\ 
HO~ 0 I 
0 OH 
Formula 2 
thereby inhibiting the cancer cell. 
0 OH 
3. The method of claim 1, wherein the compound and salts 
50 thereof is according to Formula 2 
Formula 2 
US 8,895,746 B2 
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4. The method of claim 1, wherein the cancer cell is a 
human pancreatic cancer cell. 
5. The method of claim 1, wherein the cancer cell is a 
human breast cancer cell. 
6. The method of claim 1, wherein the cancer cell is char-
acterized by an aberrant level of Stat3. 
7. A method effective to inhibit Stat3 activity in a cell, 
comprising the step of contacting the cell with a compound 10 





10. The method of claim 7, wherein the cell is a cancer cell. 
""-. O'\-~· ru 
11. The method of claim 10, wherein the cancer cell is a 
20 human pancreatic cancer cell. 
(YNl("N/\) 




12. The method of claim 10, wherein the cancer cell is a 
human breast cancer cell. 
13. The method of claim 7, wherein the Stat3 is constitu-
tively active. 
14. A method effective to down-regulate the expression of 
Stat3-regulated genes in a cell, comprising the step of con-
tacting the cell with a compound and salts thereof according NCU '° to Focmofa 1mFmmofa2 
,I~ "' ·" 
~ o,~ 
(YN'['N"\ 
HO~ 0 I 
0 OH 
thereby inhibiting Stat3 in the cell. 
8. The method of claim 7, wherein the compound and salts 
thereof is according to Formula 1 
40 
45 
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9. The method of claim 7, wherein the compound and salts 
thereof is according to Formula 2 
65 
Formula 1 
""-. \ ~· ru 
(YNl("N/S\ 
HO~ 0 I 
0 OH 
Formula 2 
thereby down-regulating Stat3 regulated genes in the cell. 
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15. The method of claim 14, wherein the compound and 
salts thereof is according to Formula 1 
Formula 1 
~ ~ \A} 
(YN'('N/\) 
HO~ 0 I 
0 OH 
16. The method of claim 14, wherein the compound and 





17. The method of claim 14, wherein the cell is a cancer 
cell. 
18. The method of claim 17, wherein the cancer cell is a 
20 
human pancreatic cancer cell. 
19. The method of claim 17, wherein the cancer cell is a 
human breast cancer cell. 
20. The method of claim 14, wherein the Stat3-regulated 
genes comprise c-Myc, Bcl.xL, matrix metalloproteinase 9, 
VEGF, or combinations thereof. 
* * * * * 
